Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 19Ovarian Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Advanced Endometrial Cancer 2Adenocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Diseases 1Ovarian Clear Cell Carcinoma 1Neoplasms, Glandular and Epithelial 1Melanoma 1Liver Neoplasms 1

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Clear Cell Carcinoma × lenvatinib × Gynecologic × Clear all
NCT05296512 2025-12-16

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Ovarian Clear Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡